BioCentury
ARTICLE | Clinical News

Subcutaneous hdm-ASIT+: Phase IIa started

October 3, 2016 7:00 AM UTC

ASIT began a double-blind, placebo-controlled, German Phase IIa trial to evaluate subcutaneous hdm-ASIT+ in about 45 allergic patients. ...